翰森制药(03692.HK) 公布,集团自研B7-H3靶向抗体–药物偶联物(ADC)注射用HS-20093获中国国家药品监督管理局批准纳入突破性治疗药物,拟定适应症为用于治疗经至少二线治疗后进展的骨肉瘤患者。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-25 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.